Table 3 CMR parameters in the study and control groups
Pompe | Controls | P-Value | |
|---|---|---|---|
N = 17 | N = 18 | ||
Heart rate, bpm | 69 ± 10 | 64 ± 12 | 0.14 |
BSA, kg/m2 | 0.9 ± 0.2 | 0.9 ± 0.2 | 0.90 |
LV-EDV index, ml/m2 | 75 ± 12 | 75 ± 15 | 0.85 |
LV-ESV index, ml/m2 | 28 ± 7 | 30 ± 7 | 0.40 |
LV-EF, % | 62 ± 6 | 61 ± 4 | 0.40 |
LV mass index, g/m2 | 48 ± 8 | 53 ± 14 | 0.17 |
LV hypertrophy, n (%) | 1 (6) | 0 (0) | 0.49 |
LV mass/volume ratio | 0.65 ± 0.10 | 0.71 ± 0.13 | 0.14 |
RV-EDV index, ml/m2 | 74 ± 14 | 77 ± 14 | 0.54 |
RV-ESV index, ml/m2 | 30 ± 9 | 32 ± 10 | 0.42 |
RV-EF, % | 60 ± 7 | 60 ± 9 | 0.73 |
LV-GLS, % | −19 ± 2.5 | −19.1 ± 2.2 | 0.93 |
LV-GRS, % | 41.3 ± 8.2 | 34.4 ± 6.9 | 0.012 |
LV-GCS, % | −20.8 ± 2.5 | −18.7 ± 2.4 | 0.015 |
LA dilatation, n (%) | 3 (18) | 0 (0) | 0.10 |
LGE, n (%) | 3 (18) | 0 (0) | 0.10 |
Global ECV, %* | 27.3 ± 4.5 | 25.4 ± 2.5 | 0.18 |
Septal ECV, %* | 28.4 ± 4.9 | 25.9 ± 2.8 | 0.12 |
LW ECV, %* | 26.2 ± 4.2 | 24.9 ± 2.5 | 0.33 |